Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


All chapters
Previous chapter Next chapter

CHAPTER 12

Kinase Inhibition for Immuno-oncology

A new era of immunotherapeutic intervention in oncology was ushered in by the approval of ipilimumab in 2011, a CTLA4 blocking antibody for the treatment of melanoma. The ensuing approval of several PD-(L)1 immune checkpoint-blockading agents demonstrated that durable responses could be realized in a disease where only a modest delay to progression was the standard outcome. All these therapeutic antibodies act through modulating the inter-cellular communication network employed by the immune system. However, such modalities are unsuited to attenuate intra-cellular signaling pathways, which currently remain the domain of small molecule therapeutics. Discussed herein are kinase targets and small molecule inhibitors thereof that have found utility in immuno-oncology. An emphasis in this review is placed on molecules and targets under clinical evaluation, although emerging areas of exciting preclinical biology will also be discussed.

Publication details


Print publication date
06 Nov 2018
Copyright year
2019
Print ISBN
978-1-78801-083-2
PDF eISBN
978-1-78801-309-3
ePub eISBN
978-1-78801-563-9
From the book series:
Drug Discovery